Skip to main content
SMMT logo

Summit Therapeutics Inc. (SMMT) Stock: Price, Forecast & Analyst Target

Summit Therapeutics Inc. (SMMT) — MoonshotScore 51/100 (Fair band), calculated Nov 18, 2026. Price $10.57 (+0.67%), as of the Nov 19, 2026 trading session; market cap $8.45B. Expected results Feb 22, 2027.

Educational signal · not a buy or sell recommendation · How to read this

Market value / cash and short-term investments: 13.42× (cash as of Sep 30, 2026) · expected results Feb 22, 2027

$10.57 +$0.07 (+0.67%) Market Cap $8.45B

Summit Therapeutics Inc. · SMMT · NASDAQ · Healthcare · Biotechnology

Research dated 2026-09-13 (results through the quarter ended Jun 2026; the quarter ended Sep 2026 not covered): Summit Therapeutics is a pre-revenue biopharmaceutical developer whose reported pipeline is concentrated in infectious-disease therapies, with ridinilazole as the flagship candidate for Clostridioides difficile infection. The case depends on whether clinical progress can produce a commercial asset before rising development spending consumes liquidity or prompts further financing.

Price as of Nov 19, 2026

Key Statistics

51 of 100

MoonshotScore v2 · Summit Therapeutics (SMMT)

Fair
Business Quality Thin (25)
Financial Safety Fortress (95)
Valuation Full (45)
Growth Durability Shrinking (10)
Momentum Quiet (40)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

A fortress balance sheet, but weak quality, stalling growth and a full valuation. Business Quality: Thin; Financial Safety: Fortress; Valuation: Full; Growth Durability: Shrinking; Momentum: Quiet.

  • EPS beat 3 of the last 8 reports
  • Altman Z 21.31 · Piotroski F 2

Holding back: weak fundamentals, soft growth

Helping: balance-sheet strength

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for SMMT (57 recorded, newest six shown)
RecordedScoreBand
53Fair
53Fair
52Fair
52Fair
51Fair
51Fair

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$10.57
Change on the day+0.67%
52-week range$10.53–$29.23
Market capitalisation$8.45B—
Price / earnings (trailing)-19.78
Shares traded on the day9.01M
Beta (volatility vs the S&P 500)-1.52

Why Summit Therapeutics scores 51

Dr. Mira Sol, the Stock Expert AI TV data character
Safety reads near the top, but growth is near the floor. That is typical of a clinical-stage drug developer.
Dr. Mira Sol · Data scientist, Stock Expert AI TV (fictional AI character)
51Fair
  • Business Quality25
  • Financial Safety95
  • Valuation45
  • Growth Durability10
  • Momentum40

Share price, last 12 months -22.3%

$20.04 $15.57

How the stock reacts to earnings

EPS beat in 4 of the last 12 reports (2023–2026); the stock still fell the next session after 3 of those beats. Average first-session move: 12.1% either way.

  1. -16.3%Nov ’23
  2. -18.9%Feb ’24
  3. +3.3%May ’24
  4. -6.2%Aug ’24
  5. -14.8%Oct ’24
  6. -18.1%Feb ’25
  7. +15.7%May ’25
  8. -10.4%Aug ’25
  9. -10.7%Oct ’25
  10. +1.1%Feb ’26
  11. -22.7%Apr ’26
  12. -7.3%Jul ’26
Next-session move EPS beat (4) EPS in line (1) EPS miss (5) EPS not reported (2)
Every report, with revenue and five-session moves
Moves run from the close before the report to the first and fifth closes after it.
ReportEPSRevenueNext session5 sessions
Miss—-7.3%-8.8%
Beat—-22.7%-17.7%
Miss—+1.1%+1.6%
Miss—-10.7%-7.3%
Miss—-10.4%-8.3%
Beat—+15.7%+2.2%
Beat—-18.1%-13.5%
Miss—-14.8%-4.3%
Beat—-6.2%+12.3%
In line—+3.3%+26.2%
——-18.9%-13.2%
——-16.3%-9.6%

For a company without product revenue, earnings tell you little. Readouts from the lung cancer trials move this stock.

What management is saying differently

Management's own words on the Q2 FY2026 call () against Q4 FY2025 (). Analysts' questions are left out.

  • New this call: “additional tumor”, “non-squamous cohorts” — none of them came up in Q4 FY2025.
  • Getting louder: “statistically significant” (4 → 8 mentions), “global phase” (1 → 7 mentions), “iii studies” (2 → 7 mentions).
  • Gone quiet: “interim pfs”, “final pfs”, “egfr mutant”, “primary endpoint” — regular themes last call, absent this time.
  • Tone: Cautious words such as “may”, “could” and “headwind” fell from 3.2 to 1.3 per 1,000 words, and confident words such as “record” and “strong” fell from 2.5 to 0.8.

Management sounded more assured, with new trial cohorts on the agenda.

Our track record on this stock

Since the score went from 47 to 51 while the share price moved -17.0% through .

MoonshotScore (0–100, band floors 45 · 65 · 80) Share price, scaled to its own range

The score has stayed in the Fair band across the stretch we have recorded; we grade each band change three months after it happens.

The crowd against our signals

  • Analysts: 65% of 23 rate it a buy; the average target sits +177.5% from the price of $10.57.
  • Last 90 days: 3 upgrades and 0 downgrades among 11 rating actions.
  • Our signals: Fair band; strongest pillar Financial Safety (95), weakest Growth Durability (10).

Analysts price a successful drug launch that our model has no way to score yet. Until revenue arrives, our reading stays cautious.

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $11, high $25, latest $11. 4 reported quarters marked, 2 above and 2 below the recorded estimate. $25 $11 high $25 Feb 23, 2026 · Earnings results · reported below the recorded estimate · close $161Apr 30, 2026 · Earnings results · reported above the recorded estimate · close $162Jul 23, 2026 · Earnings results · reported below the recorded estimate · close $143Nov 4, 2026 · Earnings results · reported above the recorded estimate · close $164 Oct 17, 2025 Nov 19, 2026 · $11 $21Oct 17, 2025$19Oct 31, 2025$18Nov 14, 2025$18Nov 28, 2025$18Dec 12, 2025$18Dec 26, 2025$20Jan 9, 2026$16Jan 23, 2026$15Feb 6, 2026$16Feb 20, 2026$15Mar 6, 2026$16Mar 20, 2026$19Apr 2, 2026$25Apr 17, 2026$16May 1, 2026$17May 15, 2026$18May 29, 2026$14Jun 12, 2026$14Jun 26, 2026$15Jul 10, 2026$14Jul 24, 2026$14Aug 7, 2026$13Aug 21, 2026$18Sep 4, 2026$18Sep 18, 2026$17Oct 2, 2026$15Oct 16, 2026$16Oct 30, 2026$14Nov 13, 2026

Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.

Events behind the price

  • · Earnings results · below the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings results · below the recorded estimate
  • · Earnings results · above the recorded estimate

Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.

Upcoming events

As of

  1. Next results dueProvider estimate
How to read these dates

Estimated dates can change.

What to watch next

Other perspectives

Council score for Summit Therapeutics (SMMT): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Weak
Financial Safety Strong
Valuation Neutral
Growth Durability Negative
Momentum Neutral

Legends Council

6 lenses, 6 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Neutral read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Unfavorable read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation

Financial Health Weak
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Weak
Debt/Equity Strong
ROE Negative
Gross Margin Negative

Read on: Nov 19, 2026

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

The Munger lens reads the current price as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Summit Therapeutics (SMMT), and what does it report?

Short answer · as of

Summit is developing therapies rather than selling an established drug portfolio.

Ridinilazole leads a pipeline aimed at bacterial infections, while other described programs target drug-resistant Enterobacteriaceae infections.

Current financial statements therefore measure development intensity and funding capacity, not product demand: recent periods show no revenue or gross profit, while research and administrative costs drive operating losses. Earlier revenue was classified as license and service revenue, so it should not be read as evidence of recurring product sales.

2 · Latest results

What do the latest results show for Summit Therapeutics (SMMT)?

Research expense increased from the preceding period, administrative expense was nearly unchanged, and operating and net losses widened. The latest loss per share landed close to the prevailing estimate after the preceding report had been less negative than expected.

Operating cash use accelerated more sharply than the accounting loss changed. Cash still increased by period end, which means the balance-sheet improvement did not come from operations; the reported figures do not establish the external funding mechanism.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Latest quarter · R&D
$169.13M Sep 30, 2026
Latest quarter · SG&A
$45.48M Sep 30, 2026
Latest quarter · FMP standardized operating result
−$214.61M Sep 30, 2026
Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026Not available$169.13M$45.48M−$214.61M
Jun 30, 2026Not available$157.73M$62.76M−$220.50M
Mar 31, 2026Not available$132.62M$62.59M−$195.21M
Dec 31, 2025Not available$147.29M$77.58M−$224.88M
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Did results meet expectations?

Reported earnings and revenue alongside the estimates recorded by the provider.

Latest report · revenue estimate
$111,111 Nov 4, 2026
Latest report · EPS vs estimate
Above estimate Nov 4, 2026
Report dateRevenue · reportedRevenue · estimateEPS · reportedEPS · estimate
Nov 4, 2026Not available$111,111−$0.2600−$0.2817
Jul 23, 2026Not available$113,889−$0.2800−$0.2744
Apr 30, 2026Not available$54,420−$0.2400−$0.3300
Feb 23, 2026Not availableProvider row rejected−$0.2900−$0.1026
How to read these figures

Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2026$0-$208M-$0.26 (diluted)
Jun 2026$0-$216M-$0.28 (diluted)
Mar 2026$0-$189M-$0.24 (diluted)
Dec 2025$0-$219M-$0.29 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Summit Therapeutics (SMMT)?

Short answer · as of

Cash and short-term investments were $629.79M at the Sep 30, 2026 balance-sheet date. Operating cash flow was −$159.81M for the quarter ended Sep 30, 2026, meaning operations used cash. These figures do not establish a cash runway.

Cash and short-term investments substantially exceed debt and total liabilities, while liquidity ratios indicate ample near-term coverage. The modeled runway extends beyond the immediate reporting calendar at the recent annualized cash-use rate.

That cushion is financing capacity, not business self-sufficiency. Operations consume cash, the burn rate has accelerated, and current revenue contributes nothing toward research spending. Net cash is also small beside the company’s market value, leaving valuation primarily exposed to pipeline outcomes rather than balance-sheet assets.

Data-derived red flags

  • Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 8 reported quarters.
  • Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.

How much cash does the business generate or use?

Quarterly operating cash flow shows cash generated or used by operations.

Latest quarter · operating cash flow
−$159.81M Sep 30, 2026
Previous quarter · operating cash flow
−$167.78M Jun 30, 2026
Period endOperating cash flowCapital expenditure (reported)
Sep 30, 2026−$159.81M−$400,000
Jun 30, 2026−$167.78M−$970,000
Mar 31, 2026−$122.29M−$240,000
Dec 31, 2025−$75.65M−$120,000
How to read these figures

Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.

4 · What to check next?

What should you watch next at Summit Therapeutics (SMMT)?

Short answer · as of

The next earnings report is expected on Feb 22, 2027. The number it tests is the $-1.07 EPS analysts carry for it.

Research expense, operating cash use and the ending cash balance deserve to be read together. Continued burn acceleration without revenue would shorten the financing window even if reported debt remains modest.

Future revenue estimates assume a transition away from the current pre-revenue profile, but the later forecasts span an exceptionally wide range. Evidence of a recurring commercial revenue stream would matter more than a narrow earnings-per-share variance while development spending remains the dominant cost.

5 · Peer comparison

How does Summit Therapeutics compare with its peers?

Short answer

Summit Therapeutics's score ranks 12th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Compared with a commercial biotechnology company, Summit currently has no product revenue, gross profit or operating cash generation to absorb development costs. Its accounts chiefly reveal how aggressively the pipeline is being funded and how much liquidity remains.

Compared with a diversified drug developer, Summit’s described pipeline is concentrated in bacterial infections, especially Clostridioides difficile and resistant Enterobacteriaceae. Low debt reduces creditor pressure, but concentrated clinical exposure and reliance on external capital make asset progress unusually important to the financial story.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Kiniksa Pharmaceuticals, Ltd. (KNSA) Same industry, near in market value$93.53 Nov 19, 2026$7.35B98 5-pillar Nov 18, 2026
Krystal Biotech, Inc. (KRYS) Same industry, near in market value$315.82 Nov 19, 2026$9.36B96 5-pillar Nov 18, 2026
Halozyme Therapeutics, Inc. (HALO) Same industry, near in market value$93.04 Nov 19, 2026$10.6B95 5-pillar Nov 18, 2026
Bio-Techne Corporation (TECH) Same industry, near in market value$72.70 Nov 19, 2026$11.4B92 5-pillar Nov 18, 2026
Corcept Therapeutics Incorporated (CORT) Same industry, near in market value$67.79 Nov 18, 2026$7.42B91 5-pillar Nov 18, 2026
TG Therapeutics, Inc. (TGTX) Same industry, near in market value$64.88 Nov 19, 2026$9.81B90 5-pillar Nov 18, 2026
Protagonist Therapeutics, Inc. (PTGX) Same industry, near in market value$127.16 Nov 18, 2026$8.30B88 5-pillar Nov 18, 2026
Royalty Pharma plc (RPRX) Named competitor$68.67 Nov 18, 2026$39.5B73 5-pillar Nov 18, 2026
Ligand Pharmaceuticals Incorporated (LGND) Same industry, near in market value$298.71 Nov 18, 2026$5.98B71 5-pillar Nov 18, 2026
Oruka Therapeutics, Inc. (ORKA) Same industry, near in market value$97.57 Nov 19, 2026$6.62B67 5-pillar Nov 18, 2026
Belite Bio, Inc. (BLTE) Same industry, near in market value$156.23 Nov 18, 2026$6.35B64 5-pillar Nov 18, 2026
Summit Therapeutics (SMMT) — this page$10.57$8.45B51
Moderna, Inc. (MRNA) Named competitor$199.33 Nov 19, 2026$80.7B31 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$20.00 – $41.00
Consensus target
$33.13
Median target
$35.50
Revenue estimate
$2.37M
EPS estimate
$-1.07

Consensus record · Captured .

Measured against a quoted price of $10.57 (as of Nov 19, 2026).

Insider activity

Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Nov 16, 2026

Transactions
13
Identified insiders
4
Purchases
6
Sales
0
Other transactions
7

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Institutional ownership
17.3% Period end Sep 30, 2026
Previous quarter · ownership
17.7% Prior to period end Sep 30, 2026
Reporting holders
333 Period end Sep 30, 2026
Previous quarter · holders
270 Prior to period end Sep 30, 2026
Holders in provider snapshotShares
Baker Bros. Advisors LP32,786,348
Blackrock, INC.10,363,750
Fmr LLC8,136,745
Vanguard Capital Management LLC7,230,441
Vanguard Portfolio Management LLC6,717,642

Tracked investors

Which of the 16 named investors we follow held SMMT in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported SMMT in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Summit Therapeutics (SMMT)?

Read these with our analysis →

Summit Therapeutics Healthcare Stock: Key Questions Answered

The last 2 questions are answered from this page's own dated data, not from the research.

What does ridinilazole mean for Summit Therapeutics?

Ridinilazole is the flagship candidate in Summit’s reported infectious-disease pipeline and is being developed as an oral treatment for Clostridioides difficile infection. Its importance is magnified because the company has no current revenue to diversify the economics.

Why does Summit Therapeutics report no revenue?

Summit is funding clinical development rather than reporting sales from an established commercial drug. Historical license and service revenue does not represent a current recurring product-sales base.

How exposed is Summit Therapeutics to rising research spending?

Research is the dominant operating expense and increased in the latest period, contributing to wider operating losses and heavier cash use. Without commercial revenue, that spending flows directly into the financing requirement.

Can Summit Therapeutics fund its infectious-disease pipeline?

Cash and short-term investments provide meaningful runway at the recent annualized burn rate, and debt is modest. Accelerating operating cash use means that runway must be reassessed as development intensity changes.

What is the SMMT stock price today?

The last price recorded for Summit Therapeutics Inc. (SMMT), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the SMMT price target?

The analyst consensus price target for Summit Therapeutics Inc. (SMMT), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 68 figures on this page — 60 from Financial Modeling Prep (FMP), 5 with no recorded source, 2 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-13), by section of the research

  • Summary at the top of the page: Legal name; Business description; Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Cash runway cross-check (ours)
  • 1. What is Summit Therapeutics (SMMT), and what does it report?: Business description; Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Revenue by segment; Most recent periodic reports
  • 2. What do the latest results show for Summit Therapeutics (SMMT)?: Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Cash and short-term investments over time (USD millions); Cash, investments and debt; Reported versus estimated, last 8 quarters
  • 3. What are the financial strengths and risks for Summit Therapeutics (SMMT)?: Cash, investments and debt; Cash and investment components; Trailing twelve-month ratio set; Cash runway cross-check (ours); Operating cash flow by quarter (USD millions); Cash against market value
  • 4. What should you watch next at Summit Therapeutics (SMMT)?: Next earnings report; Analyst revenue and earnings estimates (average); Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Cash and short-term investments over time (USD millions); Reported versus estimated, last 8 quarters
  • 5. How does Summit Therapeutics compare with its peers?: Sector / industry (provider taxonomy); Business description; Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Cash, investments and debt; Trailing twelve-month ratio set
  • FAQ: What does ridinilazole mean for Summit Therapeutics?: Business description; Quarterly income statement (USD thousands); Annual revenue and net result (USD millions)
  • FAQ: Why does Summit Therapeutics report no revenue?: Business description; Revenue by segment; Annual revenue and net result (USD millions); Quarterly income statement (USD thousands)
  • FAQ: How exposed is Summit Therapeutics to rising research spending?: Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Annual revenue and net result (USD millions)
  • FAQ: Can Summit Therapeutics fund its infectious-disease pipeline?: Business description; Cash, investments and debt; Cash runway cross-check (ours); Operating cash flow by quarter (USD millions); Cash and short-term investments over time (USD millions)
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.